Inactivating c-Met by genetic knockdown or pharmacologic treatment not only reverses the EMT process but also diminishes the CD44+CD133− CSC population in radioresistant HNSCC cells, leading to an overall reduction in tumor development and progression. This evidence concerns the gene CD44 and head and neck squamous cell carcinoma.